Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now

MRC Global (MRC) Q4 Earnings And Revenues Miss Estimates

Published 02/13/2020, 08:45 PM
Updated 07/09/2023, 06:31 AM

MRC Global Inc. (NYSE:MRC) reported weaker-than-expected results for the fourth quarter of 2019. Reduced customer spending levels adversely impacted results.

It recorded an adjusted loss per share of 35 cents per share in the reported quarter, lagging the Zacks Consensus Estimate of earnings per share of 7 cents. Notably, its earnings per share were 17 cents a year ago.

For 2019, the company’s adjusted earnings per share were 15 cents, lagging the Zacks Consensus Estimate of 61 cents. On a year-over-year basis, the bottom line declined 86%.

Segmental Revenues

In the reported quarter, MRC Global’s revenues totaled $766 million, reflecting a year-over-year decline of 24.1%. Revenues were adversely impacted by weak segmental results.

Further, the company’s revenues lagged the Zacks Consensus Estimate of $853.2 million by 10.2%.

Based on MRC Global’s product line, revenues from carbon steel pipe, fittings and flanges declined 38% year over year to $201 million, while that from valves, automation, measurement and instrumentation decreased 24.1% to $309 million, and that from gas products moved down 7.4% to $126 million. Sales for general oilfield products fell 8.3% to $88 million, while that for stainless steel alloy pipe and fittings declined 8.7% to $42 million.

Revenues from the Upstream sector were approximately $224 million, declining 33.9% from the year-ago quarter. Midstream sales totaled $298 million, down 20.1% from the year-ago quarter, while Downstream sales totaled $244 million, declining 17.8% year over year.

The company has three reportable segments — the U.S., Canada and International. Information on these segments for the quarter under review is given below:

Sales generated from the U.S. segment totaled $608 million, declining 21.9% year over year. The results were adversely impacted by weakness in upstream, midstream and downstream businesses.

Revenues from the Canada segment moved down 45.6% year over year to $43 million due to weakness in upstream, midstream and downstream businesses.

Sales from the International segment declined 24.3% to $115 million. The results were adversely impacted by weakness in upstream and downstream, partially offset by strength in the midstream business.

For 2019, the company’s revenues totaled $3.66 billion, decreasing 12.2% year over year. Also, the top line lagged the Zacks Consensus Estimate of $3.75 billion.

Margin Profile

In the quarter under review, MRC Global’s cost of sales declined 24.2% year over year to $635 million. Adjusted gross profit in the quarter moved down 27.7% year over year to $146 million. Margin slipped 90 basis points (bps) to 19.1%. Selling, general and administrative (SG&A) expenses were down 4.7% year over year to $141 million.

Adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) declined 63.5% year over year to $23 million while adjusted EBITDA margin was down 320 bps at 3%. Interest expenses were down 10% year over year at $9 million.

Balance Sheet and Cash Flow

Exiting fourth-quarter 2019, MRC Global had a cash balance of $32 million, up 28% from $25 million at the end of the last reported quarter. Long-term debt balance declined 12.2% sequentially to $547 million.

In 2019, the company generated net cash of $242 million from operating activities against $11 million used in the previous year. Capital spending totaled $18 million versus $20 million in 2018.

During 2019, the company used $75 million for repurchasing shares and $24 million for paying out dividends.

Outlook

For the quarters ahead, MRC Global is concerned about weak market conditions. However, it believes that its focus on cost reduction, lowering debts and generation of free cash flow will be advantageous.

For 2020, the company predicts revenues of $3,200-$3,700 million. As noted, revenues of the U.S. and Canada segments are expected to decline in mid-single digits, and that for International will likely be down in low-single digits. Also, sales will likely decline in high-single digits for the Upstream sector, and in mid-single digits for Midstream and Downstream sectors.

Revenues for the first quarter of 2020 are predicted to be flat sequentially.

Adjusted gross profit margin will likely be 19.6-19.8%. Selling, general and administrative expenses will likely be $510-$530 million, and adjusted EBITDA will probably be $160-$200 million. Tax rate will likely be 26-28%.

Earnings per share will probably be 19-56 cents for the year.

Cash flow from operations will likely be $110-$160 million. Capital spending is expected to be $15-$20 million.

MRC Global Inc. Price, Consensus and EPS Surprise

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

MRC Global Inc. price-consensus-eps-surprise-chart | MRC Global Inc. Quote

Zacks Rank & Stocks to Consider

With a market capitalization of $937 million, MRC Global currently carries a Zacks Rank #3 (Hold).

Some better-ranked stocks in the Zacks Industrial Products sector are Graco Inc. (NYSE:GGG) , Tennant Company (NYSE:TNC) and Barnes Group, Inc. (NYSE:B) . While Graco sports a Zacks Rank #1 (Strong Buy), Tennant and Banes Group carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

In the past 60 days, earnings estimates for the companies have improved for the current year. Further, average earnings surprise for the last four quarters was 0.40% for Graco, 28.65% for Tennant and 4.21% for Barnes Group.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>



Graco Inc. (GGG): Free Stock Analysis Report

MRC Global Inc. (MRC): Free Stock Analysis Report

Barnes Group, Inc. (B): Free Stock Analysis Report
3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Tennant Company (TNC): Free Stock Analysis Report

Original post

Zacks Investment Research

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.